ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ARVN Arvinas Inc

32.37
0.77 (2.44%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Arvinas Inc ARVN NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.77 2.44% 32.37 13:00:05
始値 安値 高値 終値 前日終値
31.73 31.04 32.72 32.37 31.60
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2505:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
2024/4/1120:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
2024/3/1905:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
2024/3/0421:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2024/2/2808:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2808:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2808:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2808:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2806:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2721:02EDGAR2Form 8-K - Current report
2024/2/2721:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
2024/2/2106:06EDGAR2Form 8-K - Current report
2024/2/2106:05GLOBEArvinas Announces Chief Financial Officer Transition
2024/2/2021:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
2024/2/1422:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
2024/2/1410:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0620:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
2024/2/0206:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
2024/1/1707:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
2024/1/1706:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/1/0906:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0821:45EDGAR2Form 8-K - Current report
2023/12/0823:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2023/12/0621:01EDGAR2Form 8-K - Current report
2023/12/0612:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
2023/12/0603:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
2023/11/2907:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
2023/11/2721:11EDGAR2Form 8-K - Current report
2023/11/2721:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
2023/11/0807:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2023/11/0806:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0721:03EDGAR2Form 8-K - Current report
2023/11/0721:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
2023/11/0220:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2023/10/2321:30EDGAR2Form 8-K - Current report
2023/10/2220:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
2023/10/1820:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
2023/10/1607:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
2023/10/1607:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
2023/9/0120:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2023/8/1506:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/0905:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0820:03EDGAR2Form 8-K - Current report
2023/8/0820:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
2023/8/0105:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
2023/7/0622:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
2023/6/1605:30GLOBEArvinas Announces Changes to its Board of Directors
2023/6/0820:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
2023/6/0520:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2023/5/0820:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..

最近閲覧した銘柄

Delayed Upgrade Clock